Stephen Hahn’s liquid biopsy company Harbinger Health raises $140M Series B to launch first cancer tests by 2025
Harbinger Health, a startup with ambitious goals to develop liquid biopsies that spot signs of cancer early, has raised $140 million in Series B funding and announced plans to begin selling its first commercial blood tests in 2025.
The Cambridge, MA-based company, which was launched by Flagship Pioneering with $50 million in 2021, has remained tight-lipped about exactly how its experimental test works. But Harbinger believes it can get the cost roughly an order of magnitude cheaper than its competition, potentially placing its price tag under $100.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
